{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:19Z","timestamp":1790949559612,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Idiopathic inflammatory myopathy (IIM) frequently coexists with interstitial pneumonia (IP) and is commonly the initial or sole manifestation accompanied by positive myositis-specific autoantibodies (MSAs), even in the absence of meeting diagnostic criteria. This study aims to evaluate the proportion of progressive pulmonary fibrosis (PPF) and identify potential predictors influencing the progression of pulmonary fibrosis in patients with MSA-IP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This descriptive study employed a retrospective cohort design, enrolling patients diagnosed with interstitial pneumonia and positive MSAs at Beijing Chao-Yang Hospital in a sequential manner. Clinical data were systematically collected from the patients\u2019 medical records during regular follow-up visits conducted every 3 to 6\u2009months. Cox regression analysis was utilized to identify independent predictors of PPF in patients with positive MSAs and interstitial pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 307 patients were included in the study, with 30.6% of them developing PPF during a median follow-up period of 22\u2009months. Kaplan\u2013Meier survival curves demonstrated a significantly lower survival in the PPF patients compared to the non-PPF patients (median 11.6\u2009months vs. 31\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.000). An acute\/subacute onset of interstitial pneumonia (HR 3.231, 95%CI 1.936\u20135.392, <jats:italic>p<\/jats:italic>\u2009=\u20090.000), lower diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 6.435, 95%CI 4.072\u201310.017, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and the presence of diffuse alveolar damage (DAD) on high-resolution computed tomography (HRCT) (HR 8.679, 95%CI 1.974\u201338.157, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) emerged as independent predictors of PPF. Notably, the implementation of triple therapy comprising glucocorticoids, immunosuppressants, and antifibrotic drugs was associated with a reduced risk of developing PPF (HR 0.322, 95%CI 0.115\u20130.899, <jats:italic>p<\/jats:italic>\u2009=\u20090.031).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 30.6% of patients with MSA-IP may develop PPF within the follow-up period. Patients presenting with an acute\/subacute onset of interstitial pneumonia, lower predicted DLCO SB% and evidence of DAD on HRCT are more susceptible to developing PPF. Conversely, the administration of triple therapy appears to serve as a protective factor against the development of PPF in patients with MSA-IP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1325082","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:28:15Z","timestamp":1704947295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study"],"prefix":"10.3389","volume":"10","author":[{"given":"Huijuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: a new classification of adult autoimmune myositis","volume":"69","author":"Sen\u00e9cal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1068402","DOI":"10.3389\/fmed.2023.1068402","article-title":"Interstitial lung disease associated with inflammatory myositis: autoantibodies, clinical phenotypes, and progressive fibrosis","volume":"10","author":"Ceribelli","year":"2023","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1007\/s00330-021-08411-w","article-title":"Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies","volume":"32","author":"Laporte","year":"2022","journal-title":"Eur Radiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","article-title":"Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis","volume":"60","author":"Vojinovic","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e023998","DOI":"10.1136\/bmjopen-2018-023998","article-title":"Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"8","author":"Kamiya","year":"2018","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3899\/jrheum.221067","article-title":"Ro52, myositis, and interstitial lung disease","volume":"50","author":"McHugh","year":"2023","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e2021047","DOI":"10.36141\/svdld.v38i4.11368","article-title":"Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies","volume":"38","author":"Lia","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"IPF consensus working group. What\u2019s in a name? That which we call IPF, by any other name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur Respir J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","article-title":"Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)","volume":"22","author":"Nasser","year":"2021","journal-title":"Respir Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2100221","DOI":"10.1183\/13993003.00221-2021","article-title":"The burden of progressive fibrotic interstitial lung disease across the UK","volume":"58","author":"Simpson","year":"2021","journal-title":"Eur Respir J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"924754","DOI":"10.3389\/fphar.2022.924754","article-title":"Prognostic predictive characteristics in patients with fibrosing interstitial lung disease: a retrospective cohort study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1265355","DOI":"10.3389\/fmed.2023.1265355","article-title":"Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Chai","year":"2023","journal-title":"Front Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model","volume":"23","author":"Hozumi","year":"2022","journal-title":"Respir Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1007\/s12325-021-01786-8","article-title":"Prevalence and incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1378\/chest.07-0104","article-title":"Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy","volume":"132","author":"Parambil","year":"2007","journal-title":"Chest"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1378\/chest.130.2.553","article-title":"Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases","volume":"130","author":"Parambil","year":"2006","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","article-title":"Interstitial lung diseases associated with amyopathic dermatomyositis","volume":"28","author":"Suda","year":"2006","journal-title":"Eur Respir J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e003150","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/keaa372","article-title":"Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/medicina59020296","article-title":"Decreased survival and lung function in progressive pulmonary fibrosis","volume":"59","author":"Platenburg","year":"2023","journal-title":"Medicina"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","article-title":"Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial","volume":"59","author":"Flaherty","year":"2022","journal-title":"Eur Respir J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1325082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:28:19Z","timestamp":1704947299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1325082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":39,"alternative-id":["10.3389\/fmed.2023.1325082"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1325082","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"article-number":"1325082"}}